Manila LGU gets 40,000 more tablets of anti-COVID drug Molnupiravir
MANILA, Philippines — The Manila City government on Monday received an additional 40,000 tablets of Molnupiravir, an anti-viral drug used in treating mild to moderate COVID-19, it procured and which will be given for free to mild coronavirus patients – even to nonresidents of the nation’s capital city.
During a Facebook live stream, Moreno announced the arrival of 20,000 tablets of Molnupiravir which can cover 500 patients. Another batch of 20,000 tablets arrived later in the day.
“Sa mga mangangailangan dahil sila ay na-infect pero mild, ito po ay libre. Mananatiling libre hanggang kaya natin,” said Moreno, a presidential aspirant in the May 2022 elections.
(To those in need who are experiencing mild symptoms, this is free. This will remain free as long as we can make it free.)
Those who are in need of the anti-viral pill are advised to reach out to the Manila Health Department and present their prescription and contact number.
Article continues after this advertisementhttps://www.facebook.com/100044580812914/posts/489520272543996/?d=n
Article continues after this advertisementThe additional tablets of Molnupiravir will augment the remaining 4,000 capsules the city government had earlier bought.
Last Monday, the city government had over 40,000 tablets of Molnupiravir on hand – 30,000 of this inventory were eventually given to mild COVID-19 patients.
“Almost 30,000 tablets were consumed by our people all over Luzon because we have extended our Molnupiravir to any person…ang importante mabuhay lang yung taop and we are happy to be of service,” Moreno said.
RELATED STORY
KGA
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.